Asston Pharmaceuticals has successfully allotted 24,10,431 equity shares of face value ₹10 each at an issue price of ₹115 per share, including a premium of ₹105 per share. According to reports from Business Standard, this allotment represents a significant capital expansion for the pharmaceutical company.
Following this allotment, the paid up equity share capital has increased to ₹10,92,27,910 comprising 1,09,22,791 equity shares of face value ₹10 each. As reported by Business Standard, this expansion demonstrates the company's commitment to strengthening its capital base for future operations and growth initiatives.
The share allotment was reported by Business Standard on September 7, 2026, indicating the company's recent capital expansion activities. The premium structure of ₹105 per share suggests strong investor demand for the pharmaceutical company's equity offerings in the current market environment.
